MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a biotech/biopharma company creating novel and emerging treatments for mental health conditions, has initiated dosing of MB22001 to patients in a landmark microdosing study for depression. This groundbreaking trial represents a global precedent and stands as the sole clinical trial authorized for the take-home usage of LSD. MB22001, an innovative, titratable form of Lysergic Acid Diethylamide (LSD) developed by MindBio, is tailored for safe and efficacious at-home microdosing in patients grappling with Major Depressive Disorder. Administered at sub-hallucinogenic levels, this therapeutic microdose is taken every third day over an 8-week span in an open-label Phase 2a clinical trial involving 20 participants. The primary objective of this Phase 2a trial is to assess the feasibility, tolerability, and effectiveness of MB22001 microdosing in individuals with Major Depressive Disorder. The outcomes of this study will lay the foundation for the progression into a significantly larger Phase 2b trial, designed as a randomized, triple-dummy controlled investigation in patients with depression. Notably, MindBio's prior clinical evaluations of MB22001 have already yielded encouraging topline data in healthy volunteers…

MindBio Therapeutics announced a significant breakthrough based on sleep data collected during randomized controlled trials of LSD-Microdosing.

The trials involved 80 participants, and a total of 3,231 nights of sleep data were analyzed.

Based on initial findings from the sleep data collected during the trials, which included the recording, measurement, and analysis of sleep patterns in both the LSD-Microdosing treatment group of 40 participants and the placebo group of 40 participants, the company confirmed positive sleep responses to its LSD-Microdosing treatment.

The advantage of microdosing LSD as opposed to macrodosing is that patients can take the drug and then get on with their day in much the same way they would when taking anti-depressant medication…